Celgene (CELG) will report Q4 results tomorrow before the market opens with a conference call to follow at 9am ET. CELG is expected to report Q4 results at 7:30am. Current Capital IQ consensus stands at EPS of $1.60 on Revenue of $3.02 bln
Guidance
- FY17 (Raised on Jan 9 at J.P. Morgan Healthcare Conference)
- Revenue in the range of $13.0-13.4 bln (Approx 18%+ growth)
- EPS in the range of $7.10-7.25 (Approx 21% y/y growth)
- Operating Margin- 150 bps improvement in
- Revlimid revenues in the range of $8.0-8.3 bln)
- Pomalyst approx $1.6 bln
- Otezla revenues in the range of $1.5-1.7 bln
- Abraxane revenues approx $1.0 bln
Q3 Recap
CELG reported Q3 (Sep) earnings of $1.58 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus of $1.48. Revenues rose 27.8% year/year to $2.98 bln vs the $2.83 bln Capital IQ Consensus.
ECHNICALS:
CELG Support hitting on 50W